Hydrogen Peroxide

Organosulfur skeletons are crucial in many fields, including pharmaceuticals and electronics. Synthesizing organosulfur skeletons requires o-bromobenzenethiols. However, conventional methods face challenges due to quick oxidation and formation of highly reactive intermediates. Researchers have now developed a new method for synthesizing o-bromobenzenethiols from aryne intermediates via bromothiolation. This method can pave the way for the synthesis of new organosulfur compounds with applications in diverse fields. Organosulfur compounds, organic compounds containing sulfur, are vital in biological processes and research fields like pharmaceuticals, biomedical imaging, agriculture, and electronics. Compounds like phenothiazine, thianthrene and thienothiophene, containing organosulfur skeletons, play pivotal roles in these domains. Multiple methods have been developed that use o-bromobenzenethiols as the key component to synthesize these compounds. This is mainly owing to the high reactivities of the thiol (sulfur atom bonded to a hydrogen atom) and bromine moieties of o-bromobenzenethiols, compounds which contain a bromine atom attached to positions one or two (ortho position) in a benzene ring next to a sulfur atom. Conventional methods to produce o-bromobenzenethiols involve addition of bromine to aniline, then using diazonium intermediates for addition of sulfur. This process poses challenges including selective addition of bromine at the ortho position, difficulty working with certain chemical groups, and the tendency of o-bromobenzenethiols to oxidize easily in air releasing unpleasant odors. Recently, scientists have found a new method with great potential to synthesize various complex aromatic compounds by selectively adding molecules on aryne intermediates. However, despite this success, creating o-bromobenzenethiols by adding a bromine molecule and a thiol group to these intermediates has been tough. This is because the sulfur-containing compounds react strongly with the aryne molecules, making it hard to control the process. To tackle this challenge, Associate Professor Suguru Yoshida and Mr. Shinya Tabata, from the Department of Biological Science and Technology, Faculty of Advanced Engineering at Tokyo University of Science, have developed a new method. Prof. Yoshida explains, "We developed a method for synthesizing stable o-bromobenzenethiol equivalents by bromothiolation of aryne intermediates with an appropriate hydrogen sulfide equivalent and an electrophilic brominating reagent, resulting in controlled reactivity at the sulfur atom which prevents subsequent additions with aryne intermediates." Their findings were made available online on 30 April, 2024 and published in Volume 26, Issue 18 of the journal Organic Letters on May 10, 2024. The researchers utilized potassium xanthate instead of hydrogen sulfide, owing to its better reactivity in aryne reactions and pentafluorophenyl bromide as an electrophilic brominating reagent. This combination allowed them to efficiently produce complex o-bromobenzenethiol equivalents called aryl xanthates. Notably, this method demonstrated good tolerance for various chemical groups and prevented the formation of unwanted products. Using aryl xanthates, the researchers prepared diverse highly functionalized organosulfur compounds, such as phenothiazines and thianthrenes, utilizing simple protocols without any foul odor, thanks to the high stability of the compounds. With readily available aryne precursors and versatile transformations achievable using o-bromobenzenethiols, this method enabled the synthesis of a wide variety of organosulfur compounds with highly fused organosulfur skeletons. Furthermore, this method holds the potential to significantly reduce the number of steps in the synthesis of multi substituted organosulfurs contributing towards drug discovery in pharmaceutical sciences. "With our method, it is now possible to synthesize sulfur-containing compounds with complex structures that are difficult to achieve using conventional methods. It can enable the development of novel organosulfur compounds that could lead to the discovery of new drugs, eco-friendly agrochemicals for sustainable agriculture, advanced materials, and organic electronics," remarks Prof. Yoshida, underscoring the potential applications of their study. This study opens new possibilities for the synthesis of organosulfur compounds with diverse applications in many fields. "Further studies on expansion of scope and applications of this method for synthesis of bioactive organosulfur compounds are underway in our laboratory," concludes a hopeful Prof. Yoshida.

FREDERICK, Md., March 11, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces a new groundbreaking study demonstrating the effectiveness of its solutions against foot-and-mouth disease virus (FMDV). This significant advancement supports the Company’s submission for an additional EPA label. Foot-and-mouth disease (FMD) represents a critical global threat, being an extremely contagious disease affecting a wide range of cloven-hoofed animals including cows, pigs, sheep, goats, and deer. The rapid spread of FMDV among livestock can lead to significant economic losses and disrupt international trade if not promptly and effectively controlled. TOMI’s recent study has proven SteraMist iHP technology to eliminate infectious FMDV from both porous (concrete) and non-porous (stainless steel) surfaces in the presence of organic soil load. This achievement meets the stringent EPA standards for demonstrating virucidal efficacy. The study, conducted by the Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T’s) Plum Island Animal Disease Center (PIADC), adhered to the strict regulatory guidelines of the U.S. Select Agent Program and utilized methods aligned with EPA-approved testing standards. Dr. Halden Shane, CEO of TOMI, emphasizes the critical nature of combating Transboundary Animal Disease (TAD) outbreaks, such as FMD, “These diseases not only disrupt domestic agricultural production but may also severely impact international trade of agricultural commodities. TADs have the potential to cause widespread economic and societal damage, particularly in regions where agricultural animals are a primary livelihood. Our mission extends into the food safety sector, aiming to halt the transmission of viruses and prevent cross-contamination. This latest study underscores our commitment to providing effective solutions in the fight against global animal diseases," Dr. Halden Shane remarked. TOMI continues conducting research to strengthen its role as a crucial advocate for advancing global health and ensuring food safety, protecting against infectious diseases. TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments. For additional information, please visit http://www.steramist.com/ or contact us at info@tomimist.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to the ability of TOMI’s products to eliminate infectious diseases. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended March 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com